Archive for January, 2016

(FDEF) Announces Share Repurchase Program

First Defiance Financial Corp. (NASDAQ: FDEF) announced today that its Board of Directors decided it is in the best interest of the Company and its shareholders to institute a new share repurchase program of up to 5%, or approximately 450,000 shares, of the common stock outstanding. Repurchases will be made periodically depending on market conditions and other factors. The repurchased shares will be held as treasury stock and will be available for general corporate purposes, including employee stock option plans. The exact number of shares to be repurchased by the company is not guaranteed.

Donald P. Hileman, President and Chief Executive Officer, said, “We believe that the repurchase of our stock is an important option within our overall capital management strategy. We completed the share repurchases under our previous authorization earlier this month and view this new authorization as an opportunity to continue offering additional value to our shareholders.”

Purchases under the First Defiance Financial Corp. stock repurchase program may be made periodically, in the open market, through block trades and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Commission or otherwise, and also in privately negotiated transactions. Depending on market conditions and other factors, these purchases may be commenced or suspended at any time or periodically without prior notice. As of January 28, 2016, First Defiance Financial Corp. had 9,009,674 shares outstanding.

First Defiance Financial Corp.

First Defiance Financial Corp., headquartered in Defiance, Ohio, is the holding company for First Federal Bank of the Midwest and First Insurance Group. First Federal operates 34 full-service branches and 41 ATM locations in northwest Ohio, southeast Michigan and northeast Indiana and a loan production office in Columbus, Ohio. First Insurance Group is a full-service insurance agency with six offices throughout northwest Ohio.

For more information, visit the company’s Web site at

Safe Harbor Statement

This news release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 B of the Securities Act of 1934, as amended, which are intended to be safe harbors created thereby. Those statements may include, but are not limited to, all statements regarding intent, beliefs, expectations, projections, forecasts and plans of First Defiance Financial Corp. and its management, and specifically include statements regarding: changes in economic conditions, the nature, extent and timing of governmental actions and reforms, future movements of interest rates, the production levels of mortgage loan generation, the ability to continue to grow loans and deposits, the ability to benefit from a changing interest rate environment, the ability to sustain credit quality ratios at current or improved levels, the ability to sell real estate owned properties, continued strength in the market area for First Federal Bank of the Midwest, and the ability to grow in existing and adjacent markets. These forward-looking statements involve numerous risks and uncertainties, including those inherent in general and local banking, insurance and mortgage conditions, competitive factors specific to markets in which First Defiance and its subsidiaries operate, future interest rate levels, legislative and regulatory decisions or capital market conditions and other risks and uncertainties detailed from time to time in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the year ended December 31, 2014. One or more of these factors have affected or could in the future affect First Defiance’s business and financial results in future periods and could cause actual results to differ materially from plans and projections. Therefore, there can be no assurances that the forward-looking statements included in this news release will prove to be accurate. In light of the significant uncertainties in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by First Defiance or any other persons, that our objectives and plans will be achieved. All forward-looking statements made in this news release are based on information presently available to the management of First Defiance. We assume no obligation to update any forward-looking statements.

As required by U.S. GAAP, First Defiance will evaluate the impact of subsequent events through the issuance date of its December 31, 2015 consolidated financial statements as part of its Annual Report on Form 10-K to be filed with the SEC. Accordingly, subsequent events could occur that may cause First Defiance to update its critical accounting estimates and to revise its financial information from that which is contained in this news release.


First Defiance Financial Corp.
Donald P. Hileman, President and CEO, 419-782-5104

Friday, January 29th, 2016 Uncategorized Comments Off on (FDEF) Announces Share Repurchase Program

(CCRN) CFO William Burns Receives South Florida Business Journal Award

The South Florida Business Journal (SFBJ) recognized Cross Country Healthcare’s Chief Financial Officer William Burns with its annual “Turnaround Achievement of the Year” award during their 9th Annual CFO Awards on Thursday, January 28, 2016.

Cross Country Healthcare President and Chief Executive Officer William Grubbs said, “I am pleased to announce that our company was honored with this prestigious award. 2015 was a year of strong revenue growth and significantly improved profitability thanks to the efforts, energy, resilience and commitment of our CFO, Bill Burns, and all of our employees.”

The SFBJ hosts the annual event to shine a spotlight on the growing importance of financial executives in the economic community. The award recognizes a CFO for strategic brilliance in leading their organization to outstanding growth and was determined by the South Florida Business Journal Editorial Team and a panelist of industry experts. This year’s event, presented by Steven Douglas Associates, took place on Thursday, January 28, 2016 at the Hyatt Regency Pier 66 on the 17th Street Causeway in Fort Lauderdale.

About Cross Country Healthcare

Cross Country Healthcare, headquartered in Boca Raton, Florida, is a national leader in providing leading-edge healthcare workforce solutions. Our solutions are geared towards assisting our clients to solve labor cost issues while maintaining high quality outcomes. With more than 30 years of experience, we are dedicated to placing highly qualified nurses and physicians as well as allied health, advanced practice, and case management professionals. We also provide both retained and contingent placement services for physicians, as well as retained search services for healthcare executives. We have more than 6,500 active contracts with a broad range of clients in both clinical and nonclinical settings, including acute care hospitals, physician practice groups, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. Through our national staffing teams and network of more than 70 branch office locations, we are able to place clinicians for travel and per diem assignments, local short-term contracts and permanent positions. We are a market leader in providing flexible workforce management solutions, including managed services programs (MSP), electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive analytics, education healthcare staffing solutions, internal resource pool consulting and development, and other consultative services.

Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at


Cross Country Healthcare, Inc.
Cheryl Rhody, 561-237-1985
Director of Marketing

Friday, January 29th, 2016 Uncategorized Comments Off on (CCRN) CFO William Burns Receives South Florida Business Journal Award

(CHLN) Announces Date For Proposed Reverse Stock Split

XI’AN, China, Jan. 29, 2016  — China Housing & Land Development, Inc. (NASDAQ: CHLN) (the “Company”) announced today that the Company’s board of directors (the “Board”) set record and effective dates for the previously announced 1-for-50,000 reverse stock split of the Company’s common stock (the “Reverse Stock Split”).  At a meeting held on January 28, 2016 Beijing time the Board unanimously approved a record date of February 15, 2016 and an effective date of February 18, 2016 for the Reverse Stock Split.

As described in the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on December 31, 2015, the Company’s stockholders approved the Reverse Stock Split at a special meeting of the Company’s stockholders held on December 30, 2015 Beijing time (December 29, 2015 U.S. Eastern Time).   Implementation of the Reverse Stock Split is expected to reduce the number of the Company’s stockholders of record to less than 300 and allow the Company to “go private” by terminating its registration under the Securities Exchange Act of 1934 and removing its common stock from quotation on the NASDAQ.

About China Housing & Land Development, Inc.
Based in Xi’an, the capital city of China’s Shaanxi province, China Housing & Land Development, Inc. is a leading developer of residential and commercial properties in northwest China and the first Chinese real estate development company traded on NASDAQ.  China Housing has been engaged in land acquisition, development, and management, including the sales of residential and commercial real estate properties through its wholly-owned subsidiary in China, since 1992.

Safe Harbor
Certain statements herein that reflect management’s expectations regarding future events are forward-looking in nature and, accordingly, are subject to risks and uncertainties, which is covered under the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995.  Such statements include, among others, all assumptions, expectations, predictions, intentions or beliefs about future events.  Forward-looking statements can be identified by the use of forward-looking terminology such as “will,” “believes,” “expects” or similar expressions.  Such information is based upon expectations of our management that were reasonable when made but may prove to be incorrect.  All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and based upon premises with respect to future business decisions, which are subject to change.  We do not undertake to update the forward-looking statements contained in this press release.  Among others, the following risks, uncertainties and other factors could cause actual results to differ from those set forth in the forward-looking statements: the risk that the Transaction may be delayed or may not be consummated; risks related to the diversion of management’s attention from our ongoing business operations; the effect of the announcement of the proposed Transaction or operational activities taken in anticipation of the Transaction on our business relationships, operating results and business generally; the outcome of any legal proceedings that have been or may be instituted against us related to the Transaction; and the amount of the costs, fees, expenses and charges related to the Transaction.  For a description of additional risks and uncertainties that may cause actual results to differ from the forward-looking statements contained in this press release, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), and our subsequent SEC filings.  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system at

For additional information please contact:
Ms. Jing Lu, Chief Operating Officer, Director, and Investor Relations Officer
+86 29.8258.2639 (Email:

Mr. Qingwei Liu
+86 29.8332.8813 (Email:

Friday, January 29th, 2016 Uncategorized Comments Off on (CHLN) Announces Date For Proposed Reverse Stock Split

(UHAL) U.S. Growth City No. 6: College Station, Texas A&M are Popular Choices

Incoming Trucks Account for 53.7 Percent of U-Haul Traffic in Aggieland

COLLEGE STATION, Texas, Jan. 29, 2016  — The official “Home of the 12th Man” is home to a lot of U-Haul do-it-yourself movers.

College Station made the U-Haul Top 10 U.S. Growth Cities for 2015 at No. 6. Growth rankings are determined by the net gain of incoming one-way U-Haul truck rentals versus outgoing rentals for the past calendar year.

Read the entire College Station release, including additional quotes, facts, statistics, infographics and photos at

U-Haul locations in College Station saw 53.7 percent of truck rental customers coming into the city as opposed leaving, and welcomed 1 percent more U-Haul arrivals and departures year-over-year.

Texas A&M University is the city’s largest employer and centerpiece of the Bryan-College Station metro area with an enrollment of nearly 60,000 students.

“A&M continues to grow, and College Station is seeing a lot of growth in apartment and retail buildings – retail on the first floors and housing above,” said Matt Merrill, president of U-Haul Company of West Houston. “The overall business market continues to grow for U-Haul there.”

The housing and jobs sectors have been on the upswing in College Station, according to multiple reports, adding appeal to the area at a time when other Texas cities have been hurt by the slumping oil sector.

Texas A&M’s 2012 move to the Southeastern Conference only helped College Station and the Aggies’ sports profile, which translated to a massive football stadium expansion project. And based on the U-Haul trucks pulling into town, there should be plenty of people to fill those seats.

“The community is close-knit and the city is very well managed, very clean and very well kept,” Merrill said. “The crime rate is very low. It’s a very friendly place even though it continues to grow. Everybody comes in and says hello – and they’re darn sure not Yankees.”

While U-Haul migration trends don’t correlate directly to population or economic growth, the growth cities data is a strong gauge of how well cities are attracting and keeping residents. The report was compiled from more than 1.7 million one-way U-Haul truck transactions that occurred in 2015. All cities were considered, regardless of size.

Discover the U-Haul Top 10 U.S. Growth Cities named so far and continue following the countdown at and via Twitter @uhaul.


Jeff Lockridge
Sebastien Reyes
Phone: 602-263-6194

Friday, January 29th, 2016 Uncategorized Comments Off on (UHAL) U.S. Growth City No. 6: College Station, Texas A&M are Popular Choices

(XENT) Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany

Decision Represents Early Step in Building the Company’s Foundation Internationally

Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that InEk, the German Institute for the Hospital Remuneration System, has assigned NUB (Neue Untersuchungs und Behandlungsmethoden) Status 1 for mometasone furoate implants for 2016.

The purpose of the NUB process is to support the initial introduction of new and innovative medical products by allowing a limited number of participating hospitals to receive reimbursement. NUB Status 1 is the highest priority designation available, and was only assigned to a minority of product submissions for 2016.

“We believe that the robust clinical evidence supporting PROPEL was key to this favorable decision, which we received on the first application round,” stated Lisa Earnhardt, president and chief executive officer, Intersect ENT. “While our focus as a company is very much on U.S. commercialization as well as development of our pipeline products, this represents an important step in our efforts to build a foundation for international expansion over the coming years.”

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit

Forward-Looking Statements

The statements in this press release regarding the ability of hospitals to negotiate for additional funding to cover the cost of procedures and Intersect ENT’s ability to expand its business internationally are “forward-looking” statements. These forward-looking statements are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. These statements include those related to the review of data by and timing for approval by the FDA as well as the rate of patient adoption for Intersect ENT’s products, if approved. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, the performance of PROPEL and PROPEL mini, the development of competitive products, the uncertain timing of completion of and the success of clinical trials and market competition. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Intersect ENT’s filings on Form 10-K, Form 10-Q and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.



Media Contact:
for Intersect ENT, Inc.
Nicole Osmer, 650-454-0504
Investor Contact:
Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105

Friday, January 29th, 2016 Uncategorized Comments Off on (XENT) Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany

(MCRB) Announces Participation at Two Upcoming Investor Conferences

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will participate in two investor conferences in February:

  • Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday, Feb. 2, 2016 in New York, NY.
  • Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in New York, NY.

Roger Pomerantz, M.D., Chairman, President and CEO of Seres, will participate in a question and answer session on the first day of the Leerink Partners Global Healthcare Conference. The session will be available under the Investors and Media section of Seres’ website at A replay of the session will become available approximately one hour after the event and will be archived on the site for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres’ most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring Clostridium difficile infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).


IR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
PR Contact:
Ten Bridge Communications
Dan Quinn, 781-475-7974

Friday, January 29th, 2016 Uncategorized Comments Off on (MCRB) Announces Participation at Two Upcoming Investor Conferences

(TRXC) to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

TransEnterix, Inc. (NYSE MKT: TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria Hotel in New York. The presentation is scheduled to take place at 3:05 pm Eastern Time on Thursday, February 11, 2016.

To access the live audio webcast or archived recording, use the following link The replay will be available on the company’s website.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at


TransEnterix, Inc.
Investor Contact:
Mark Klausner, 443-213-0501
Media Contact:
Mohan Nathan, 919-917-6559

Thursday, January 28th, 2016 Uncategorized Comments Off on (TRXC) to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

(CBMG) Announces Chairman of Board, CEO Appointment

SHANGHAI, China and CUPERTINO, Calif., Jan. 28, 2016  — Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the election of Terry A. Belmont as Chairman of the Board of Directors, and the appointment of Tony (Bizuo) Liu to Chief Executive Officer, effective February 7, 2016.

The Board of Directors of CBMG issued the following statement: “We are delighted that Terry Belmont, a well-respected and seasoned healthcare veteran, will be leading CBMG’s strategic growth efforts as independent Chairman of the Board of Directors. Having recently retired as CEO of University of California, Irvine Health, Mr. Belmont brings an extensive array of experience in large-scale health sector institutions along with vast corporate and community Board experience, all of which will continue to serve CBMG well. The Board expresses its sincere appreciation for the tireless efforts of outgoing Chairman, Wentao (Steve) Liu for his guidance and leadership, and are grateful for his business experience as he continues to serve as a Director and strategic advisor to CBMG’s management team.”

The Board also confirmed the appointment of Tony (Bizuo) Liu, currently Chief Financial Officer, to the position of Chief Executive Officer. “The depth and breadth of Tony’s multinational strategic planning, finance and investment experience combined with his tenure at CBMG will be a tremendous asset in leading CBMG through its next phase of growth and success,” commented Chairman Terry Belmont. “I am confident that Tony will excel in his new role as the company continues to fortify its technology platforms and enlarge its development pipelines.”

Tony Liu commented, “Biotechnology, analogous to the technology companies I have led, is prime for innovation and disruption and I look forward to leading the development of CBMG’s immuno-oncology and stem cell research programs and driving clinical patient benefits in these exciting fields. CBMG is well on its way to being a leader in this domain as we strategically position the Company to monetize our growing cellular therapy programs, deliver value to our stakeholders and serve large patient populations under a world-class infrastructure. I’m pleased to lead the Company through this important stage of growth and success.”

Tony Liu will continue to serve as the Company’s Chief Financial Officer while an executive search for a successor is underway.

About Terry A. Belmont 
Mr. Belmont has been serving CBMG as an Independent Director since December 2013 and as Vice Chairman of the Board since March 2015.

Mr. Belmont has over 35 years of experience in leading major medical centers and healthcare entities with multi-campus responsibilities.  Before he retired from his CEO position at University of California, Irvine Health in June 2015, Mr. Belmont had lead the transition of this medical center into a leading regional and nationally recognized healthcare system. Among his notable accomplishments at UC Irvine Health, Mr. Belmont added the state of the art Douglas Hospital as part of UC Irvine Medical Center, a 7 story clinical laboratory building, the establishment or outpatient centers throughout the Orange County Region, the development of affiliated healthcare networks to serve the entire region and, most importantly, partnered with the leadership of the School of Medicine in significantly improving the medical center’s quality of care reputation throughout the United States.

From 2006 to 2009 Mr. Belmont served as CEO of Long Beach Memorial Medical Center and Miller Children’s Hospital. He has also served as president and chief executive officer in St. Joseph Hospital of Orange, Pacific Health Resources, California Hospital Medical Center and HealthForward.  He continues to participate in several healthcare organizations in improving continuity of care in various California communities.

Mr. Belmont’s community involvement has included board positions with the March of Dimes, Orange County World Affairs Council, Southern California College of Optometry, American Heart Association and Children’s Fund. He also serves on the Board of Trustees of the University of Redlands. He was also a founding board member of Pacificare Health Systems, which was acquired by United Healthcare in early 2000.  Mr. Belmont received his master’s in public health with a major in hospital administration from UC Berkeley, and a bachelor’s in business from the University of Redlands.

About Tony (Bizuo) Liu
Mr. Liu began serving CBMG as an Independent Director and Chairman of the Audit Committee in March 2013, after which he was appointed as Chief Financial Officer in January 2014.

Previously, Mr. Liu served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, he held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global ecommerce platform.  He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles.  He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process.  Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director.  He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.  Tony obtained his Washington State CPA certificate in 1992.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases.  Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of nine independent cell production lines, are designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884

Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
Thursday, January 28th, 2016 Uncategorized Comments Off on (CBMG) Announces Chairman of Board, CEO Appointment

(STRS) Carl E. Berg Announces Receipt Of Unsolicited Portfolio Offer

CUPERTINO, Calif., Jan. 28, 2016  — Carl E. Berg, the largest shareholder (17.6%) of Stratus Properties Inc. (Nasdaq: STRS), today announced that on January 25, 2016, he received from Capretta Properties Inc. a copy of Capretta’s January 22 letter of intent to Stratus offering to purchase substantially all of Stratus’s real estate properties for $435 million cash.  The terms of the offer provide for the properties to be transferred to Capretta free of existing debt, which Capretta noted in the letter aggregated approximately $255.6 million on September 30, 2015.  Capretta’s nine-page letter of intent was addressed to William Armstrong, Stratus’ CEO, and indicates that Capretta sent copies of the letter to Stratus’ five largest stockholders, including Mr. Berg.  The letter describes Capretta’s offer as representing “an offer equal to $21.60 per share net of existing debt” for Stratus’s real estate portfolio alone.  Capretta also notes in the letter that Stratus has “other assets, including cash, that total over $6.00 per share” and, as a result, Capretta’s offer “presents a financial return to Stratus far in excess of its current stock price in the $19.00 range.”  Mr. Berg understands that statement to mean that Capretta’s offer implies a liquidation value of Stratus of approximately $27.60 per share (pretax). Capretta’s offer states that it is not subject to any financing contingency and that no real estate brokerage commissions will be payable by either party.

Capretta Properties is a privately owned real estate development and investment company that was established in 1989 and is based in Mill Valley, California.

Mr. Berg said: “After having submitted for a vote at the 2016 Annual Meeting a proposal requesting Stratus’ Board of Directors to engage an investment banker to explore a sale of Stratus, I am delighted to learn that four months before the expected date of that annual meeting Stratus has received an unsolicited offer from a credible party to purchase all of Stratus’ real estate assets. To me, Capretta’s offer appears to have significant merit and represents an excellent point from which to begin the process of exploring the sale of Stratus.  I definitely agree that Stratus should not incur any brokerage fees in connection with selling its real estate portfolio in response to a third party’s unsolicited offer to purchase Stratus’ real estate assets.  After the Stratus shareholders have endured years of underperformance by Stratus, the Board – including its two recent Board appointees, James Joseph and John Wenker – needs to seriously and objectively evaluate Capretta’s offer and any other offers that Stratus receives, with the aim of allowing Stratus’ stockholders to realize the full value of Stratus’ real estate portfolio.  I repeat what I wrote on December 19, 2015 to each Board member:  I will hold them accountable for any lack of independence, unsound business decisions or failure to live up to their legal obligations to the Stratus shareholders. I am making today’s announcement because all of the shareholders deserve to know that Stratus has received this significant offer, but Stratus has made no public statement to its owners about the offer.”

Capretta’s president, Ricardo Capretta, addressed the letter of intent to Stratus’s Chairman and CEO William Armstrong, and begins the letter by stating:  “I have tried to contact you on five separate occasions now [December 12 and 18, 2015; January 4, 19 and 20 of 2016].  I appreciate that you returned one of my calls on January 19….  I have not received a second return phone call….  At this point, it does not seem as though I will hear back from you so therefore I thought it might be more productive to forward you an unsolicited offer for your assets since they are possibly going to be offered for sale soon.  I understand that potential suitors have, or are considering submitting unsolicited offers, in the near future.”

Stratus is a real estate company engaged primarily in the development, management, operation and sale of commercial, hotel, entertainment, and multi- and single-family residential real estate properties located in Texas, primarily in the Austin, Texas area.

Mr. Berg is a real estate investor and venture capitalist and was the Chief Executive Officer of Mission West Properties, a real estate investment trust, from 1997 through December 22, 2012, when that company was sold to DivcoWest, a privately owned real estate investment company.  He believes he has been Stratus’ largest shareholder for almost the last 15 years.

Carl E. Berg
10050 Bandley Drive
Cupertino, California 95014
(408) 725-0700

Thursday, January 28th, 2016 Uncategorized Comments Off on (STRS) Carl E. Berg Announces Receipt Of Unsolicited Portfolio Offer

(BBEPP) Partners Declares Monthly Distributions for Preferred Units

Breitburn Energy Partners LP (NASDAQ:BBEP) announced today distributions for its 8.25% Series A Cumulative Redeemable Perpetual Preferred Units (NASDAQ: BBEPP) and 8% Series B Perpetual Convertible Preferred Units. A cash distribution of $0.171875 per Series A Unit is payable on March 15, 2016, to record holders of its Series A Units at the close of business on February 29, 2016. This monthly distribution is equal to an annual distribution of $2.0625 per Series A Unit. Breitburn has elected to pay the distribution on its Series B Units in kind by issuing additional Series B Units instead of paying a cash distribution. A distribution of 0.006666 PIK unit per Series B Unit is payable on February 15, 2016, to record holders of Series B Units at the close of business on January 29, 2016.

About Breitburn Energy Partners LP

Breitburn Energy Partners LP is a publicly traded, independent oil and gas master limited partnership focused on the acquisition, development, and production of oil and gas properties throughout the United States. Breitburn’s producing and non-producing crude oil and natural gas reserves are located in the following seven producing areas: Ark-La-Tex, Michigan/Indiana/Kentucky, the Permian Basin, Mid-Continent, the Rockies, Florida, and California. See for more information.

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Breitburn expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Breitburn based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict, including those which are set forth under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, and if applicable, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.

Non-U.S. investors are not eligible holders of Breitburn common, Series A Units, and Series B Units. This press release is intended to provide a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of Breitburn’s distributions to non-U.S. investors as being attributable to income that is effectively connected with a U.S. trade or business. Accordingly, Breitburn’s distributions to non-U.S. investors are subject to federal income tax withholding at the highest applicable effective tax rate.



Breitburn Energy Partners LP
Antonio D’Amico
Vice President, Investor Relations & Government Affairs
Jessica Tang
Investor Relations Manager
(213) 225-0390

Thursday, January 28th, 2016 Uncategorized Comments Off on (BBEPP) Partners Declares Monthly Distributions for Preferred Units

(CIFC) Engages JPMorgan to Assist in Exploration of Strategic Alternatives

NEW YORK, Jan. 28, 2016  — CIFC LLC (NASDAQ:CIFC) and its subsidiaries (collectively “CIFC” or the “Company”) announced the engagement of JPMorgan Securities LLC to assist the Company and management in exploring a range of strategic alternatives to enhance shareholder value and to capitalize on its industry-leading platform.  Those alternatives may include a sale of the Company or the sale of a stake in the Company to a strategic investor with the objective of accelerating the Company’s existing growth and diversification initiatives.

The Company has not made a decision to enter into any transaction at this time and there can be no assurance that exploration of its strategic alternatives will result in a transaction and there is no set timetable for actions to be taken in the process.  The Company does not intend to discuss or disclose any developments related to the process until the Board has approved a definitive course of action or otherwise concludes the process.

About CIFC
Founded in 2005, CIFC is a private debt manager specializing in secured U.S. corporate loan strategies with approximately $14.2 billion of assets under management as of September 30, 2015. Headquartered in New York, CIFC is an SEC registered investment adviser and is listed on NASDAQ. The firm currently serves more than 200 institutional investors globally. For more information, please visit CIFC’s website at

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements regarding future results or expectations. Forward-looking statements can be identified by forward-looking language, including words such as “believes,” “anticipates,” “expects,” “estimates,” “intends,” “may,” “plans,” “projects,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made, various operating assumptions and predictions as to future facts and conditions, which may be difficult to accurately make and involve the assessment of events beyond CIFC’s control. Caution must be exercised in relying on forward-looking statements. The forward-looking statements in this release are subject to risks and uncertainties, and the other risks related to CIFC’s business that are described in its annual report on Form 10-K. The forward-looking statements contained in this press release are made as of the date hereof, and CIFC undertakes no obligation to update any forward-looking statement to reflect subsequent events, new information or circumstances arising after the date hereof.


CONTACT: Investor Relations at or +1 (212)-624-4508
Thursday, January 28th, 2016 Uncategorized Comments Off on (CIFC) Engages JPMorgan to Assist in Exploration of Strategic Alternatives

(AMDA) to Present Research Supporting Favorable Silicon Nitride Findings

Four Scientific Presentations Demonstrate Superiority of Silicon Nitride Over Existing Biomaterials

SALT LAKE CITY, Jan. 28, 2016  — Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurring March 5-8, 2016 in Orlando, Florida.

“Our presentations will demonstrate the rationale for using our proprietary silicon nitride composition in a variety of medical applications within the $15 billion surgical spine, dental, hip and knee replacement markets,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “This scientific data will convincingly demonstrate the serious limitations of other existing biomaterials, while highlighting the advantages of silicon nitride, even as we continue further testing on an improved second generation silicon nitride composition. I’m very proud of our continued innovation and robust science, which will be presented at this important orthopedic forum.”

Accepted submission titles and their authors include:

  • Metal Ions Contribute to the Material Instability of Zirconia Toughened Alumina – Giuseppe Pezzotti, Leonardo Puppulin, Marco Boffelli, Nobuhiko Sugano, Bryan J. McEntire (Presenter), and B. Sonny Bal
  • Differential Bacterial Expression on Silicon Nitride, PEEK, and Titanium Surfaces – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti
  • Do Ceramic Femoral Heads Contribute to Polyethylene Oxidation? – Bryan J. McEntire (Presenter), Yuto Enomoto, Wenliang Zhu, Marco Boffelli, Elia Marin, B. Sonny Bal, and Giuseppe Pezzotti
  • Differential Effects of Hydrothermal Ageing on the Surface Fracture Toughness of Ceramics – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti

The ORS annual meeting attracts attendees from all over the world—clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who come together to present the latest innovative and cutting-edge musculoskeletal research.

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit

About Orthopaedic Research Society
Orthopaedic Research Society (ORS) exists to promote, support, develop and encourage research in surgery and musculoskeletal disease and disciplines. Every year, the ORS meeting attracts over 3,000 attendees with an interest in orthopaedic research including clinicians, surgeons, residents, veterinarians, basic scientists, and engineers.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica’s future performance, business operations and acceptance of its technology platform. Statements relating to Amedica’s market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica’s products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Mike Houston
VP, Commercialization

Robert Haag
IRTH Communications

Thursday, January 28th, 2016 Uncategorized Comments Off on (AMDA) to Present Research Supporting Favorable Silicon Nitride Findings

(MRCY) to Present at Cowen & Company 37th Annual Aerospace/Defense Conference

CHELMSFORD, Mass., Jan. 27, 2016  — Mercury Systems, Inc. (NASDAQ:MRCY) (, announced that it will participate in the Cowen and Company 37th Annual Aerospace/Defense Conference to be held February 3-4, 2016, at the Lotte New York Palace Hotel in New York City. Management will present an overview of the Company’s business Wednesday, February 3rd, at 10:30 a.m. ET.

The presentation will be webcast live and may be accessed from the investor section of Mercury’s website at A replay of the webcast will be available for 90 days.

Mercury Systems – Innovation That Matters

Mercury Systems (NASDAQ:MRCY) is the better alternative for affordable, secure and sensor processing subsystems designed and made in the USA. Optimized for program and mission success, Mercury’s solutions power a wide variety of critical defense and intelligence applications on more than 300 programs such as Aegis, Patriot, SEWIP, F-35 and Gorgon Stare. Headquartered in Chelmsford, Massachusetts, Mercury Systems is a high-tech commercial company purpose-built to meet rapidly evolving next-generation defense electronics challenges. To learn more, visit

Mercury Systems and Innovation That Matters are trademarks of Mercury Systems, Inc.

Gerry Haines, CFO
Mercury Systems, Inc.
Wednesday, January 27th, 2016 Uncategorized Comments Off on (MRCY) to Present at Cowen & Company 37th Annual Aerospace/Defense Conference

(ALQA) Announces Agreement With HealthTrust

LANGHORNE, Pa., Jan. 27, 2016  — Alliqua BioMedical, Inc. (Nasdaq:ALQA) (“Alliqua” or “the Company”), a provider of advanced wound care products, today announces that it has signed a national group purchasing agreement with HealthTrust. The agreement, which became effective on Jan. 1, 2016, added Alliqua’s Biovance® Human Amniotic Membrane Allograft (“Biovance”) to HealthTrust’s regenerative tissue wound care contracting category.

Biovance is intended for use as a biological membrane covering applied in the treatment of a wide range of wounds and in surgical procedures. Common uses are on partial- and full-thickness acute and chronic wounds and, in surgery, to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or scar formation.

“We are pleased to be selected as a HealthTrust supplier as we work toward increasing access in the marketplace to all of our wound care technologies,” said Brad Barton, Chief Operating Officer of Alliqua BioMedical.

About Alliqua BioMedical, Inc.

Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds.

Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company’s Mist Therapy System® uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.

In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua’s electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua’s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Langhorne, PA and Eden Prairie, MN.

For additional information, please visit To receive future press releases via email, please visit

About HealthTrust

HealthTrust (legally known as Healthtrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust ( serves over 1,400 acute care facilities and members in more than 22,300 other locations, including ambulatory surgery centers, physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tennessee, HealthTrust is an affiliate of Parallon Business Solutions, LLC (, a leading provider of healthcare business and operational services, including revenue cycle management, workforce and technology solutions. On Twitter @healthtrustpg and @parallonconnect.

Legal Notice Regarding Forward-Looking Statements:

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses;  price increases for supplies and components; and the inability to carry out research, development and commercialization plans.  In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.


Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
Wednesday, January 27th, 2016 Uncategorized Comments Off on (ALQA) Announces Agreement With HealthTrust

(NLST) Federal Circuit Denies Inphi Rehearing On LRDIMM Patent Case

Supreme Court appeal now only recourse to challenge 60 claims covering the operation of LRDIMM

IRVINE,Calif., Jan. 27, 2016  — Netlist, Inc. (NASDAQ: NLST), announced today that the U.S. Court of Appeals for the Federal Circuit has denied Inphi’s petition for a rehearing of its November 2015 precedential opinion which had affirmed the validity of  U.S. Pat. No. 7,532,537 (“‘537 Patent”).

This final decision by the Federal Circuit is a landmark victory for Netlist’s ‘537 patent after more than four years of scrutiny in the US Patent and Trademark Office and one year of appeals in the federal court system. In order to continue to challenge the validity of this patent, Inphi must now appeal directly to the U.S. Supreme Court.

“The denial of Inphi’s petition for rehearing is for all practical purposes, the final step in the complete validation of the ‘537, one of Netlist’s seminal LRDIMM patents,” said Netlist’s Chief Executive Officer, C.K. Hong.  “With more than thirty U.S. and foreign patents broadly covering fundamental aspects of LRDIMM, this final decision by the Federal Circuit puts us in the strongest possible position to pursue licensing opportunities in the fast growing LRDIMM market.”

According to De Dios & Associates, the LRDIMM market was estimated to be $3 billion in 2015 and is projected to reach around $7 billion by 2018.

About Netlist, Inc.
Netlist creates solutions that accelerate turning data into information. We design and manufacture controller and software-based memory solutions for our OEM and Hyperscale customers in the server and storage space. Flagship products NVvault® and EXPRESSvault™ accelerate system performance and provide mission critical fault tolerance. HyperVault®, Netlist’s next-generation architecture, expands the performance and capacity of memory channel storage. The company holds a portfolio of patents, many seminal, in the area of hybrid memory, rank multiplication and load-reduction, among others. To learn more, visit

Safe Harbor Statement:
This news release contains forward-looking statements regarding future events and the future performance of Netlist. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expected or projected. These risks and uncertainties include, but are not limited to, our ability to regain compliance with NASDAQ listing rules, risks associated with the launch and commercial success of our products, programs and technologies; our capital resources; the success of product partnerships; continuing development, qualification and volume production of HyperVault™, EXPRESSvault™, NVvault®, HyperCloud® and VLP Planar-X RDIMM; the timing and magnitude of the decrease in sales; our ability to leverage our NVvault® and EXPRESSvault™ technology in a more diverse customer base; the rapidly-changing nature of technology; risks associated with intellectual property, including risks associated with the inherent uncertainty of the litigation process; patent infringement litigation against us as well as the costs and unpredictability of litigation over infringement of our intellectual property and the possibility of our patents being reexamined by the United States Patent and Trademark office; volatility in the pricing of DRAM ICs and NAND; changes in and uncertainty of customer acceptance of, and demand for, our existing products and products under development, including uncertainty of and/or delays in product orders and product qualifications; delays in the Company’s and its customers’ product releases and development; introductions of new products by competitors; changes in end-user demand for technology solutions; the Company’s ability to attract and retain skilled personnel; the Company’s reliance on suppliers of critical components and vendors in the supply chain; fluctuations in the market price of critical components; evolving industry standards; and the political and regulatory environment in the People’s Republic of China. Other risks and uncertainties are described in the Company’s annual report on Form 10-K filed on March 27, 2015, and subsequent filings with the U.S. Securities and Exchange Commission made by the Company from time to time. Except as required by law, Netlist undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:
Investors: Press:
Brainerd Communicators, Inc. Brainerd Communicators, Inc
Mike Smargiassi/Jenny Perales Sharon Oh
(212) 986-6667 (212) 986-6667
Wednesday, January 27th, 2016 Uncategorized Comments Off on (NLST) Federal Circuit Denies Inphi Rehearing On LRDIMM Patent Case

(SBSA) Calibash 2016 Raises Bar As Most Successful Urban Music Concert in LA

LOS ANGELES, Jan. 27, 2016  — Spanish Broadcasting System, Inc. (SBS) (NASDAQ: SBSA), the favorite station of millennial youth in Los Angeles, MEGA 96.3FM successfully hosted Calibash 2016, the most anticipated urban and rhythmic music concert in Los Angeles featuring world renowned artists Snoop Dogg and Lil Jon as well as the hottest Latin music singers today including J Balvin, Prince Royce, Nicky Jam, Plan B, Yandel, Farruko, Becky G, J Alvarez, Justin Quiles, Zion & Lennox and Henry Santos. The sold-out Calibash 2016, hosted by KXOL Mega 96.3FM, LaMusica and produced by AEG Live and Latin Events took place on Sunday, January 24, 2016 at STAPLES Center in Los Angeles, California.

As one of the most important and climaxing moments of the night, J Balvin invited Justin Bieber to the stage to perform the remix of the hit song “Sorry.” Lil Jon, Becky G and Yandel also performed for the first time their upcoming single “Take It Off.”  Calibash continues to be the perfect platform for showcasing upcoming music hits and new artists’ collaborations given the massive media coverage and social media interaction the event enjoys. But the stars were not only onstage, celebrities such as Floyd Mayweather, Larry Hernandez, Yasiel Puig, Jonathan Sanchez, Adriel Favela, Martin Castillo, Kurupt were seen in attendance.

During CALIBASH 2016, SBS revealed the LaMusica app logo above the stage. LaMusica is the company’s mobile music product that offers exclusive content including live streams of SBS’ market-leading radio stations and talent, a “My Radio” innovative personalization tool, hundreds of expertly curated playlists as well as social networking features and access to more than 23 million songs. The app is available for free download at the Apple store and Google Play.

“I’m so proud of SBS LA’s team effort and positive contributions; #CALIBASH2016 broke attendance records, revenue records and showcased the most popular current Latin and English artists. Mega 96.3FM signature event CALIBASH entertained the Los Angeles millennials through mobile, digital and social media making the event a top trending topic across various platforms,” stated Marko Radlovic, Senior Vice President and West Coast Regional Manager at Spanish Broadcasting System.

“Music festivals and concerts come and go but very few grow into a reputable brand as Calibash has. With a sold-out concert, Mega 96.3FM once again has proven to enjoy the loyal following of bilingual and bicultural millennials and provides them a top of the line event that features the most popular English and Spanish language music singers preferred by this coveted consumer group,” said Juan Carlos Hidalgo, West Coast VP of Programming at Spanish Broadcasting System.

“Over the 9 years that AEG Live has been producing the event, this was its biggest year yet. We were proud to bring together a stellar line-up of the hottest new generation acts, as well as established heavy hitters in the Latin and General market space. Along with exciting surprise guests, the 4 hour high energy party had all of STAPLES on their feet for a party you didn’t want to miss,” stated Hans Schafer, Director of Latin Talent at AEG Live / Goldenvoice.

Calibash 2016 was sponsored by Bud Light, McDonalds, Southern CA Toyota Dealers, Jack Daniels, Vallarta Supermarkets, Open Road Films, LA Care Covered, Pampers, Vicks Vapor and Ford. Continue the conversation about Calibash 2016 on social media using #Calibash2016.

About Spanish Broadcasting System, Inc.
Spanish Broadcasting System, Inc. is the largest publicly traded Hispanic-controlled media and entertainment Company in the United States. SBS owns and operates 20 radio stations in the top U.S. Hispanic markets of New York, Los Angeles, Miami, Chicago, San Francisco and Puerto Rico, airing the Tropical, Mexican Regional, Spanish Adult Contemporary, Spanish Oldies and Urbano format genres. SBS also operates AIRE Radio Networks, a national radio platform that creates, distributes and markets leading Spanish-language radio programming to over 100 affiliated stations reaching 88% of the U.S. Hispanic audience. The Company also owns and operates MegaTV, a television operation with over-the-air, cable and satellite distribution and affiliates throughout the U.S. and Puerto Rico. SBS also produces live concerts and events and owns 21 bilingual websites, including, an online destination and mobile app providing content related to Latin music, entertainment, news and culture. For more information, visit us online at

About AEG Live
AEG Live, the live-entertainment division of Los Angeles-based AEG, is dedicated to all aspects of live contemporary music performance. AEG Live is comprised of touring, festival, broadcast, merchandise and special event divisions, fifteen regional offices and owns, operates or exclusively books thirty-five state-of-the-art venues. The current and recent concert tour roster includes artists such as Alicia Keys, American Idols, Bon Jovi, Carrie Underwood, Daughtry, Enrique Iglesias, Jennifer Lopez, Justin Bieber, Kenny Chesney, Leonard Cohen, Paul McCartney, Taylor Swift, The WHO, Trey Songz and Juanes. The company is also currently producing residency shows at The Colosseum at Caesars Palace in Las Vegas including Celine Dion, Rod Stewart and Shania Twain and is the exclusive promoter at The Joint at Hard Rock Hotel & Casino Las Vegas. AEG Live is also the largest producer of music festivals in North America from the critically acclaimed Coachella Valley Music & Arts Festival to Stagecoach Country Music Festival and New Orleans Jazz & Heritage Festival.

Media Contacts:

Vladimir Gomez – Director of Communications & National Promotions – Spanish Broadcasting System, Inc. (SBS) – – (786) 394-9000 ext. 1144

Daniel Morales – Tapiz Media –

Wednesday, January 27th, 2016 Uncategorized Comments Off on (SBSA) Calibash 2016 Raises Bar As Most Successful Urban Music Concert in LA

(CVLT) Announces Global Customer Momentum

— Growth seen in all regions, across a variety of industries —

TINTON FALLS, N.J., Jan. 27, 2016  — Commvault (NASDAQ: CVLT), a global leader in enterprise data protection and information management, today announced continued customer momentum driven by the increased demand for Commvault data management solutions that span virtual, cloud, SaaS and traditional on premise to solve complex challenges caused by rapidly changing technology, tightening resource requirements, and ever-expanding volumes of data.

New and existing customers that have expanded their investment into Commvault’s portfolio of data management solutions and/or services in Q3 FY 2016 include, but are not limited to, the following organizations:

  • BP– BNP Paribas Partners for Innovation
  • CIECH Group
  • City of Seattle
  • Dataline
  • DataSpring
  • Guthrie Healthcare Systems
  • Hero Cycles Limited & Associates
  • Metropolitan Council of Minnesota
  • NTT Data
  • Reasonnet
  • Tinkoff Bank
  • University of Melbourne

“Data backup and protection is critical for high-availability datacenters,” said Martin Smekal, CEO of DataSpring. “That was the main reason for choosing Commvault, as it will allow us to offer the best services for backup, protection and deduplication in cloud environments with Virtual infrastructure friendly licensing policies.”

Following the launch of the Commvault Data Platform and an innovative software and service portfolio on October 20, 2015, these organizations are leveraging a variety of solutions and services to activate their data, unlock useful business insights and drive value from their new technology investments in Commvault.

“We are excited to bring on these customers in our 3rd quarter and believe our growth speaks volumes about Commvault’s ability to meet emerging data management requirements in the marketplace today,” said N. Robert Hammer, chairman, president and CEO of Commvault. “We look forward to continuing this momentum based on the recent launch of our market leading Commvault Data Platform and next generation software, which provide organizations with a modern, holistic data management solution to tackle emerging and existing challenges facing customers today.”

For more information on how to become a Commvault customer, please visit:

About Commvault
Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform modern data environments. With solutions and services delivered directly and through a worldwide network of partners and service providers, Commvault solutions comprise one of the industry’s leading portfolios in data protection and recovery, cloud, virtualization, archive, file sync and share. Commvault has earned accolades from customers and third party influencers for its technology vision, innovation, and execution as an independent and trusted expert. Without the distraction of a hardware business or other business agenda, Commvault’s sole focus on data management has led to adoption by companies of all sizes, in all industries, and for solutions deployed on premise, across mobile platforms, to and from the cloud, and provided as-a-service. Commvault employs more than 2,000 highly skilled individuals across markets worldwide, is publicly traded on NASDAQ (CVLT), and is headquartered in Tinton Falls, New Jersey in the United States. To learn more about Commvault — and how it can help make your data work for you — visit

Safe Harbor Statement: Customers’ results may differ materially from those stated herein; Commvault does not guarantee that all customers can achieve benefits similar to those stated above. This press release may contain forward-looking statements, including statements regarding financial projections, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of software products and related services, general economic conditions and others. Statements regarding Commvault’s beliefs, plans, expectations or intentions regarding the future are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from anticipated results. Commvault does not undertake to update its forward-looking statements. The development and timing of any product release as well as any of its features or functionality remain at our sole discretion.

©1999-2016 Commvault Systems, Inc. All rights reserved. Commvault, Commvault and logo, the “C hexagon” logo, Commvault Systems, Solving Forward, SIM, Singular Information Management, OnePass, Commvault Galaxy, Unified Data Management, QiNetix, Quick Recovery, QR, CommNet, GridStor, Vault Tracker, InnerVault, Quick Snap, QSnap, IntelliSnap, Recovery Director, CommServe, CommCell, ROMS, Commvault Edge, and CommValue are trademarks or registered trademarks of Commvault Systems, Inc. All other third party brands, products, service names, trademarks, or registered service marks are the property of and used to identify the products or services of their respective owners. All specifications are subject to change without notice.

Wednesday, January 27th, 2016 Uncategorized Comments Off on (CVLT) Announces Global Customer Momentum

(MNKD) to Hold Investor Conference Call on February 3, 2016

VALENCIA, Calif., Jan. 27, 2016  — MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016.

Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Medical Officer, Raymond Urbanski.

To view and listen to the webcast, visit MannKind’s website at and click on the “MannKind 2/3/16 Conference Call” link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41729996. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4172 9996#. A replay will also be available on MannKind’s website for 14 days.

As with past calls, the Company will take live questions from covering analysts.  However, departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call should email them to

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Matthew J. Pfeffer
Chief Executive Officer

Wednesday, January 27th, 2016 Uncategorized Comments Off on (MNKD) to Hold Investor Conference Call on February 3, 2016

(YRCW) Adds Former Senior Con-way Freight and FedEx Freight Executives

Also Introduces New Senior VP of Sales and Marketing

OVERLAND PARK, Kan., Jan. 26, 2016  — YRC Freight, a subsidiary of YRC Worldwide (NASDAQ:YRCW), recently announced the addition of senior executives from Con-way Freight and FedEx Freight with more than 80 years’ combined experience in the freight industry to its leadership team.

Chet Richardson has been named the Vice President of Transportation. Chet is a former Con-way Freight executive with 31 years’ experience in the LTL industry. During his time at Con-way Freight, he served as Service Center Manager, Region Manager, as well as Director and Vice President of Linehaul.

Paul Lorensen will lead the central divisions operations as Division Vice President. Lorensen comes to YRC Freight from Con-way Freight, where he most recently served as Central Area Vice President of Operations. Prior to that position, Lorensen managed several terminals and also served in several roles for Con-way Freight, including Director of Operations, Director of Quality, and Director of Solutions Engineering. He has 31 years’ industry experience.

Don Hinkle was named the new Vice President of Equipment Services. Hinkle has spent more than 23 years in all areas of terminal operations, as well as fleet maintenance. A previous YRC Freight employee, Hinkle returns to the company following 13 years with FedEx Freight. During his time at FedEx Freight, Hinkle held officer positions including Vice President of Fleet Maintenance, Safety and Transportation, and Vice President of Transportation.

The company also named Tim Haitz as the new Senior Vice President of Sales and Marketing. A 30-year YRC Freight veteran, Haitz has served primarily in sales roles, including his previous position as Vice President of Sales. He has previously worked as Terminal Manager, Vice President of Sales, and Corporate Account Executive.  Tim was promoted to this role after Bill Crowe, a 30-year veteran of YRC Freight, announced his retirement.

Darren Hawkins, President of YRC Freight, said the changes were a symbol of the momentum the company has gained over the past few years and a testament to the quality of professionals that are reaching out to YRC Freight.  “As a result, I am pleased to announce these additions to our team. It is a priority to invest in the people, technology and talent to drive the company forward,” Hawkins said. “The addition of these highly experienced and industry respected professionals demonstrates the investments we are making in our people and our company. Now is the time to be excited about YRC Freight.”

About YRC Freight

YRC Freight, a leading transporter of industrial, commercial and retail goods, specializes in less-than-truckload (LTL) shipping solutions for businesses. Based in Overland Park, Kan., YRC Freight provides comprehensive North American coverage and offers a broad portfolio of LTL services to bring flexibility and reliability to customers’ supply chains. For more information, visit

Follow YRC Freight on Twitter:

About YRC Worldwide

YRC Worldwide Inc., headquartered in Overland Park, Kan., is the holding company for a portfolio of less-than-truckload (LTL) companies including YRC Freight, YRC Reimer, Holland, Reddaway, and New Penn. Collectively, YRC Worldwide companies have one of the largest, most comprehensive LTL networks in North America with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide companies offer industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit for more information.

Media Contact: 
Mike Kelley
Tuesday, January 26th, 2016 Uncategorized Comments Off on (YRCW) Adds Former Senior Con-way Freight and FedEx Freight Executives

(HSGX) to Present at 18th Annual BIO CEO & Investor Conference

WALTHAM, Mass., Jan. 26, 2016  — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference’s Regenerative Medicine track at the Waldorf Astoria in New York, NY.  The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at  The webcast will be available on Histogenics’ website for 30 days following the conference.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit


Investor Relations
Tel: +1 (781) 547-7909
Tuesday, January 26th, 2016 Uncategorized Comments Off on (HSGX) to Present at 18th Annual BIO CEO & Investor Conference